Comparative Pharmacology
Head-to-head clinical analysis: MERREM IV versus VABOMERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MERREM IV versus VABOMERE.
MERREM IV vs VABOMERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Meropenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Vabomere is a combination of meropenem, a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), and vaborbactam, a beta-lactamase inhibitor that protects meropenem from degradation by certain serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and Klebsiella pneumoniae carbapenemase (KPC).
1 g intravenously every 8 hours over 15-30 minutes for complicated intra-abdominal infections; 500 mg intravenously every 8 hours for complicated skin and skin structure infections.
Vabomere (meropenem and vaborbactam) 4 g (meropenem 2 g and vaborbactam 2 g) intravenously every 8 hours infused over 3 hours.
None Documented
None Documented
Terminal elimination half-life approximately 1 hour in adults with normal renal function; prolonged to 4–6 hours in moderate renal impairment and up to 10 hours in severe impairment; clinical context: dosing interval adjustment required for CrCl <50 mL/min.
The terminal elimination half-life is approximately 1 hour for meropenem and 2 hours for vaborbactam in patients with normal renal function. This short half-life supports three-times-daily dosing in patients with creatinine clearance ≥50 mL/min.
Primarily renal (approximately 70% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal excretion accounts for ~20% as microbiologically inactive metabolite; minimal nonrenal clearance.
Vabomere (meropenem and vaborbactam) is primarily excreted renally. Approximately 40-50% of meropenem and 75-95% of vaborbactam are excreted unchanged in urine. Biliary/fecal excretion is minimal (<2% for both).
Category C
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic